Quantitative Archives - TBC repository

Home
/
Projects

Quantitative

Knowledge of tuberculosis and vaccine trial preparedness in Lima, Peru

2017

Study asseses knowledge and perception of TB among people in Lima, Peru with particular attention to their willingness and preparedness to participate in a future TB vaccine trial. It examined factors that could influence participation, including knowledge of TB, attitudes towards vaccination, and willingness to participate in research.

Acceptability of a proposed new tuberculosis vaccine among people deprived of liberty in Brazil

2025

Hypothetical vaccines

Assesses acceptance of a hypothetical new TB vaccine and factors associated with vaccine hesitancy among people deprived of liberty in Brazil. The study surveyed 941 people across eight prison units in six Brazilian cities. It found 95.2% reported that they would accept a new TB vaccine if available

ZAMSA-TB: Advancing epidemiological methods for surveillance of Mycobacterium tuberculosis infection

2024-2028

Hypothetical vaccines, M72/AS01e

Multi-country study developing and validating clinic-based convenience sampling of Mtb immunoreactivity (IGRA) in children aged 1-5 as a sentinel measure of recent TB transmission. Outputs include geospatial identification of high-transmission neighbourhoods to target adult/adolescent vaccine delivery, and Monte Carlo simulations to size convenience-sampling surveys able to detect population-level vaccine effectiveness during roll-out.

Tuberculosis Integrated Model-Based Evidence and Recommendations (TIMBER) for robust TB vaccine decision-making by National Immunization Technical Advisory Groups (NITAGs) in Africa.

2025 - 2028

Hypothetical vaccines

The TIMBER study is a multi-country research study aimed at strengthening the use of model-based evidence to support national decision-making on the introduction of new TB vaccines in Africa. The study brings together National Immunization Technical Advisory Groups (NITAGs), policymakers, researchers, modellers and other stakeholders in South Africa, Kenya and The Gambia to co-create models and explore how modelling can be used effectively within the WHO Evidence-to-Recommendation process. TIMBER will generate country-specific evidence, strengthen capacity for using modelling in vaccine policy decisions, and develop practical approaches to support timely, evidence-informed introduction of new TB vaccines.

Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers

One or more new adult TB vaccines could become available in the next 5-7 years. To assess willingness to receive a new TB vaccine, we conducted a household- and facility-based survey among adult community members and healthcare workers (HCWs), respectively, in Lusaka, Zambia

New tuberculosis vaccines are in late-stage trials, but how confident is the public in high burden countries in vaccines?

With tuberculosis (TB) vaccine candidates in late-stage trials, it is important to prepare for implementation to avoid delays upon licensure. General confidence in vaccines has been identified as an anticipated barrier to introducing new TB vaccines. In the absence of detailed TB specific vaccine acceptability and confidence data, we analysed currently available vaccine confidence data in countries appearing on one of the World Health Organization (WHO) high burden lists to investigate vaccine confidence in countries with a high TB burden

IGRA prevalence study

2024-2025

A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials

TB vaccine advocacy and acceptance in South Africa

2024

Gathering a range of perspectives to provide early-stage insights into TB vaccine advocacy and acceptance in South Africa

Insights into TB vaccine acceptability among adolescents in Khayelitsha through community engagement

Initially designed as an internal assessment of the impact of engagement workshops, we used short surveys to understand high-school learner perspectives of vaccines, focusing on COVID 19, TB and HIV vaccines. Between 2022 and 2024, we collected responses from 350 adolescents (14-18 years old). All participants live in Khayelitsha, where high rates of TB (4224 cases notified in the last year) intersect with socio-economic challenges

Epidemiologic study to assess the IGRA positivity in populations with a high TB

2021 - 2024

M72/AS01e

Tuberculosis (TB) vaccine efficacy trials evaluating prevention of disease must be feasible in size and duration and would ideally take place at clinical trial sites that enroll from communities with the highest incidence rates. In preparation for the Phase 3 trial of the investigational M72/AS01E-4 vaccine, we conducted a multi-country study, using interferon gamma release assay (IGRA) positivity as a proxy for expected incidence of TB. In addition to the above objects, the results from this study could help in in new vaccine introduction to identfy TB hotspot areas.